International journal of cancer. Journal international du cancer
-
Raman spectroscopy is a unique vibrational spectroscopic technique which can be used to probe biochemicals and biomolecular structures and conformations of tissues. The main objective of this study is to evaluate the feasibility of applying near-infrared (NIR) Raman spectroscopy for identification of nonneoplastic lesions (Helicobacter-pylori (Hp) infection, and intestinal metaplasia (IM)) highly associated with stomach cancer. A rapid-acquisition NIR Raman spectroscopic system was used for tissue Raman measurements at 785 nm excitation, and a total of 88 gastric tissue samples (57 normal; 11 Hp-infection; 20 IM) from 56 patients were measured. ⋯ Significant spectral differences in Raman spectra were observed among normal, Hp-infection and IM gastric tissue, particularly in the spectral ranges of 848-917, 960-1015, 1088-1133, 1206-1213, 1277-1313, 1395-1445, 1517-1549, 1607-1690, and 1714-1767 cm(-1) which contained signals related to proteins, lipids and porphyrin. PCA-LDA algorithms developed together with leave one patient out, cross validation technique yield diagnostic sensitivities of 91.7%, 80.0%, and 80.0%, and specificities of 80.0%, 100%, and 92.7%, respectively, for classification of normal, Hp-infection and IM gastric tissues. This work demonstrates the utility of NIR Raman spectroscopy for early diagnosis of Hp-infection and IM lesions in the gastric at the molecular level.
-
Recent research advances show that tumor cell intravasation (entry into the circulation) and metastasis occur very early in breast cancer progression. Clinical studies also illustrate the potential importance of detection of circulating tumor cells (CTCs) in outcomes of patients with metastatic breast cancer. Whether these cells exhibit the invasiveness and express tumor stem or progenitor markers, hallmark of the metastatic phenotype, is less well characterized. ⋯ CAM-captured cells were capable of propagation in culture. Gene expression and multiplex flow cytometric analyses on CAM-captured cells demonstrated the existence of distinct populations of CTCs including these of epithelial lineage and stem or progenitor cells. Thus, CAM-initiated CTC detection provides advantages for examining invasiveness and tumor progenitor phenotypes.
-
Excess adiposity is associated with increased risks of developing adult malignancies. To inform public health policy and guide further research, the incident cancer burden attributable to excess body mass index (BMI >or= 25 kg/m(2)) across 30 European countries were estimated. Population attributable risks (PARs) were calculated using European- and gender-specific risk estimates from a published meta-analysis and gender-specific mean BMI estimates from a World Health Organization Global Infobase. ⋯ Endometrial, post-menopausal breast and colorectal cancers accounted for 65% of these cancers. This analysis quantifies the burden of incident cancers attributable to excess BMI in Europe. The estimates reported here provide a baseline for future modelling, and underline the need for research into interventions to control weight in the context of endometrial, breast and colorectal cancer.
-
The high frequency of epidermal growth factor receptor (EGFR) mutations in tyrosine kinase inhibitor-responsive non-small-cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating EGFR mutations in guiding the clinical use of EGFR-targeted therapies. However, specimen source and methods for EGFR mutation analysis are limited by tissue availability and technical feasibility in clinical application. Therefore, the current study is designed to establish a blood-based approach for the assessment of EGFR mutations in NSCLC patients, in particular the advanced stage, and to test its clinical application. ⋯ In the patients treated with gefitinib as a second-line therapy, those with plasma EGFR mutation have a prolonged median progression-free survival compared with those with EGFR wild type (7.609 vs. 2.877 months, p = 0.002). On comparing the efficacy of gefitinib with that of docetaxel, it was found that the median progression-free survival was significantly longer for patients treated with gefitinib than those with docetaxel in those harboring plasma EGFR mutation (7.609 vs. 3.192 months, p = 0.006). These results suggest that the blood-based EGFR mutations test has the ability to provide a reliable guidance for clinical decision making for the treatment of the advanced NSCLC patients.